A group of lymphomas displaying molecular, morphologic, immunophenotypic, and clinical overlap between classical Hodgkin lymphoma and diffuse large B-cell lymphoma. This term particularly applies to m...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for B-cell lymphoma, unclassifiable, is limited due to its rarity and the complexity of its clinical features, which overlap with other lymphoma types. This overlap makes systematic clinical studies challenging, and as a result, the understanding of its genetic and phenotypic characteristics is still evolving. The condition affects a relatively small population, which further restricts comprehensive research efforts.
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in lymphomas, particularly those familiar with rare and unclassifiable types. While no specific patient organizations are currently identified for this condition, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov may provide valuable information. Additionally, inquire about any opportunities to participate in natural history studies or registries that may arise as research progresses.
There are currently two FDA-approved treatments for this condition: nivolumab and pembrolizumab. Additionally, there are several orphan drugs designated for development, including (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one and anti-CD30 Fc engineered humanized monoclonal antibody. However, no active clinical trials are currently available. For more information on ongoing research, you can search ClinicalTrials.gov for related studies.
Actionable guidance for navigating care for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in lymphomas, particularly those familiar with rare and unclassifiable types. While no specific patient organizations are currently identified for this condition, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov may provide valuable information. Additionally, inquire about any opportunities to participate in natural history studies or registries that may arise as research progresses.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for B-cell lymphoma, unclassifiable, is limited due to its rarity and the complexity of its clinical features, which overlap with other lymphoma types. This overlap makes systematic clinical studies challenging, and as a result, the understanding of its genetic and phenotypic characteristics is still evolving. The condition affects a relatively small population, which further restricts comprehensive research efforts.
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in lymphomas, particularly those familiar with rare and unclassifiable types. While no specific patient organizations are currently identified for this condition, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov may provide valuable information. Additionally, inquire about any opportunities to participate in natural history studies or registries that may arise as research progresses.
There are currently two FDA-approved treatments for this condition: nivolumab and pembrolizumab. Additionally, there are several orphan drugs designated for development, including (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one and anti-CD30 Fc engineered humanized monoclonal antibody. However, no active clinical trials are currently available. For more information on ongoing research, you can search ClinicalTrials.gov for related studies.
Actionable guidance for navigating care for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in lymphomas, particularly those familiar with rare and unclassifiable types. While no specific patient organizations are currently identified for this condition, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov may provide valuable information. Additionally, inquire about any opportunities to participate in natural history studies or registries that may arise as research progresses.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for B-cell lymphoma, unclassifiable, is limited due to its rarity and the complexity of its clinical features, which overlap with other lymphoma types. This overlap makes systematic clinical studies challenging, and as a result, the understanding of its genetic and phenotypic characteristics is still evolving. The condition affects a relatively small population, which further restricts comprehensive research efforts.
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in lymphomas, particularly those familiar with rare and unclassifiable types. While no specific patient organizations are currently identified for this condition, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov may provide valuable information. Additionally, inquire about any opportunities to participate in natural history studies or registries that may arise as research progresses.
There are currently two FDA-approved treatments for this condition: nivolumab and pembrolizumab. Additionally, there are several orphan drugs designated for development, including (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one and anti-CD30 Fc engineered humanized monoclonal antibody. However, no active clinical trials are currently available. For more information on ongoing research, you can search ClinicalTrials.gov for related studies.
Actionable guidance for navigating care for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in lymphomas, particularly those familiar with rare and unclassifiable types. While no specific patient organizations are currently identified for this condition, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov may provide valuable information. Additionally, inquire about any opportunities to participate in natural history studies or registries that may arise as research progresses.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Consider asking your healthcare providers these condition-specific questions
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.